Live from ASCO 2023 | Ascentage Pharma Releases Updated Data

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Related Keywords

United States , Li Zhang , Zhejiang , China , Rockville , Western Australia , Australia , Hong Kong , Suzhou , Jiangsu , American , Yifan Zhai , Ascentage Pharma , National Reimbursement Drug List , Astrazeneca , American Society Of Clinical Oncology , Sun Yat Sen University Cancer Center , China National Medical Products Administration , Major National , Md Anderson Cancer Center , Dana Farber Cancer Institute , Poster Discussion , American Society , Clinical Oncology , Principal Investigator , Sun Yat Sen University Cancer , Chief Medical Officer , Lung Cancer , Non Small Cell , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Cancer Center , Mayo Clinic ,